USDMF No. 17971, USFDA Approved, CEP: R1-CEP2008-121-Rev01, UK GMP, Stability Studies In Zone IVB
|Documents||CEP, USFDA Approved, USDMF|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Flumazenil is an imidazo-benzodiazepine derivative, effective in reversing benzodiazepine-induced activities. Flumazenil antagonizes the benzodiazepine binding site of the gamma-aminobutyric acid (GABA)/benzodiazepine receptor complex in the central nervous system (CNS), thereby preventing the chloride channel opening events and inhibiting neuronal hyperpolarization. As a result, flumazenil reverses benzodiazepine-induced effects including sedation, psychomotor deficits, amnesia, and hypoventilation in a dose-dependent manner.
Flumazenil, Flumazenilo, Flumazenilum, Flumazepil, Flumazenilo, Romazicon, Anexate, Mazicon, Lanexat, ethyl 8-fluoro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271 +A13(1)